Pharmacological treatments for personality disorders

References

• Arndt, I.O., Dorozynski, L., McLellan, A.T., Woody, G.E., O'Brien, C.P. (1992). Controlled study of desipramine treatment of cocaine dependence in methadone treated patients. Archives of General Psychiatry, 49, 888–893.
   PubMed Web of Science ®Google Scholar
• Arndt, I.O., McClellan, A.T., Dorozynsky, L., Woody, G.E., O'Brien, C.P. (1992). Desipramine treatment for cocaine dependence: Role of antisocial personality disorder. Journal of Nervous and Mental Disease, 182, 151–156.
   Google Scholar
• Baker-Glenn, E., Steels, M., Evans, C. (2010). Use of psychotropic medication among psychiatric out-patients with personality disorder. Psychiatrist, 34, 83–86.
   Google Scholar
• Battaglia, J., Wolff, T.K., Wagner-Johnson, D.S., Rush, A.J., Carmody, T.J., Basco, M.R. (1999). Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology, 14, 361–372.
   PubMedGoogle Scholar
• Binks, C.A., Fenton, M., McCarthy, L., Lee, T., Adams, C.E., Duggan, C. (2006). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews (1):CD005653.
   Google Scholar
• Bogenschutz, M.P., Nurnberg, G.H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104–109.
   PubMed Web of Science ®Google Scholar
• Coccaro, E.F., Kavoussi, R.J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry, 54, 1081–1088.
   PubMed Web of Science ®Google Scholar
• Cowdry, R.W., Gardner, D.L. (1988). Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111–119.
   PubMed Web of Science ®Google Scholar
• De la Fuente, J.M., Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479–486.
   PubMed Web of Science ®Google Scholar
• Duggan, C., Huband, N., Smailagic, N., Ferriter, M., Adams, C. (2009). The use of pharmacological treatments for people with personality disorder: A systematic review of randomized controlled trials. Personality and Mental Health, 2, 119–170.
   Google Scholar
• Evidence-Based Medicine Working Group (1992). Evidence-based medicine: A new approach to teaching the practice of medicine. Journal of the American Medical Association, 268, 2420–2425.
   PubMed Web of Science ®Google Scholar
• Frankenburg, F.R., Zanarini, M.C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442–446.
   PubMed Web of Science ®Google Scholar
• Herpertz, S.C., Zanarini, M.C., Schulz, C.S., Siever, L., Lieb, K., Moller, H.J., Task Force on Personality Disorders, WFSBP (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry, 8, 212–244.
   PubMed Web of Science ®Google Scholar
• Hollander, E., Swann, A.C., Coccaro, E.F., Jiang, P., Smith, T.B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621–624.
   PubMed Web of Science ®Google Scholar
• Hollander, E., Tracy, K.A., Swann, A.C., Coccaro, E.F., McElroy, S.L., Wozniak, P., …, Nemeroff, C.B. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology, 28, 1186–1197.
   PubMed Web of Science ®Google Scholar
• Ingenhoven, T., Lafay, P., Rinne, T., Passchier, J., Duivenvoorden, H. (2010). Effectiveness of pharmacotherapy for severe personality disorders; meta-analyses of randomized controlled trials. Journal of Clinical Psychiatry, 71, 14–25.
   PubMed Web of Science ®Google Scholar
• Ioannidis, J.P.A. (2005). Why most published research findings are false. PLoS Medicine, 2, e124.
   PubMed Web of Science ®Google Scholar
• Kavoussi, R.J., Coccaro, E.F. (1998). Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Journal of Clinical Psychiatry, 59, 676–680.
   PubMed Web of Science ®Google Scholar
• Kendall, T., Pilling, S., Tyrer, P., Duggan, C., Burbeck, R., Meader, N., Taylor, C. (2009). Borderline and antisocial personality disorders: Summary of NICE guidance. National Institute of Clinical Excellence. Available online: http://www.nice.org.uk/
   Google Scholar
• Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., Scoboria, A., Moore, T.J., Johnson, B.T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5, e45.
   PubMed Web of Science ®Google Scholar
• Koenigsberg, H.W., Harvey, P.D., Mitropoulou, V., Schmeidler, J., New, A.S., Goodman, M., …, Siever, L.J. (2002). Characterizing affective instability in borderline personality disorder. American Journal of Psychiatry, 159, 784–788.
   PubMed Web of Science ®Google Scholar
• Lieb, K., Vollm, B., Rucker, G., Timmer, A., Stoffers, J.M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. xBritish Journal of Psychiatry, 196, 4–12.
   PubMed Web of Science ®Google Scholar
• Leal, J., Ziedonis, D., Kosten, T. (1994). Antisocial personality disorder as a prognostic factor for pharmacotherapy of cociane depnedience. Drug and Alcohol Dependence, 35, 31–35.
   PubMed Web of Science ®Google Scholar
• Leone, N.F. (1982). Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry, 43, 148–150.
   PubMed Web of Science ®Google Scholar
• Linehan, M.M. (1993). Dialectical Behavior Therapy for Borderline Personality Disorder. New York: Guilford.
   Google Scholar
• Links, P.S., Steiner, M., Boiago, I., Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of Personality Disorders, 4, 173–181.
   Google Scholar
• Markowitz, P.J., Calabrese, J.R., Schulz, S.C., Melzer, H.Y. (1991). Fluoxetine in the treatment of borderline and schizo-typal personality disorders. American Journal of Psychiatry, 148, 1064–1067.
   PubMed Web of Science ®Google Scholar
• Markowitz, P.J., Wagner, S.L. (1995). Venlafaxine in the treatment of borderline personality disorder.Psychopharmacology Bulletin, 31, 773–777.
   PubMedGoogle Scholar
• Mercer, D., Douglass, A.B., Links, P.S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of Personality Disorders, 23, 156–174.
   PubMed Web of Science ®Google Scholar
• Newcomer, J.W., Haupt, D.W. (2006). The metabolic effects of antispsychotic medication. Canadian Journal of Psychiatry, 51, 480–491.
   PubMed Web of Science ®Google Scholar
• Newton-Jones, G., Tyrer, P., Johnson, T. (2006). Personality disorder and the outcome of depression: Meta-analysis of published studies. British Journal of Psychiatry, 188, 13–20.
   PubMedGoogle Scholar
• Nickel, M.K., Nickel, C., Mitterlehner, F.O., Tritt, K., Lahmann, C., Leiberich, P.K., …, Loew, T.H. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515–1519.
   PubMed Web of Science ®Google Scholar
• Nickel, M.K., Muechlbacher, M., Nickel, C., Kettler, C., Gil, F.P., …, Fartacek, R. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833–838.
   PubMed Web of Science ®Google Scholar
• Nose, M. (2009). No significant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms. Evidence Based Mental Health, 12, 89, doi:10.1136/ ebmh.12.3.89.
   PubMedGoogle Scholar
• Nose, M., Cipriani, A., Biancosino, B. (2009). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345–353.
   Google Scholar
• Oldham, J.M., Gabbard, G.O., Goin, M.K., Gunderson, J., Soloff, P., Spiegel, D., …, Phillips, K.A. (2001). Practice guideline for the treatment of borderline personality disorder. American Journal of Psychiatry, 158, S1–52.
   Web of Science ®Google Scholar
• Paris, J. (2008). Prescriptions for the Mind. New York: Oxford University Press.
   Google Scholar
• Paris, J. (2010a). Effectiveness of differing psychotherapy approaches in the treatment of borderline personality disorder. Current Psychiatry Reports, 12, 56–60.
   PubMed Web of Science ®Google Scholar
• Paris, J. (2010b). The Use and Misuse of Psychiatric Drugs. London: Wiley.
   Google Scholar
• Paris, J., Gunderson, J.G., Weinberg, I. (2007). The interface between borderline personality disorder and bipolar spectrum disorder. Comprehensive Psychiatry, 48, 145–154.
   PubMed Web of Science ®Google Scholar
• Parsons, B., Quitkin, F.M., McGrath, P.J., Stewart, J.W., Tricamo, E., Ocepek-Welikson, K., …, Nunes, E. (1989). Phenelzine, imipramine and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology Bulletin, 25, 524–534.
   PubMedGoogle Scholar
• Philipsen, A., Schmahl, C., Lieb, K. (2004a). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196–199.
   PubMed Web of Science ®Google Scholar
• Philipsen, A., Richter, H., Schmahl, C., Peters, J., Rusch, N., Bohus, M., Lieb, K. (2004b). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414–1419.
   PubMed Web of Science ®Google Scholar
• Rinne, T., van den Brink, W., Wouters, L., van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048–2054.
   PubMed Web of Science ®Google Scholar
• Salzman, C., Wolfson, A.N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., …, Miyawaki, E. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23–29.
   PubMed Web of Science ®Google Scholar
• Schulz, S.S., Zanarini, M.C., Bateman, A., Bohus, M., Detke, H.D., Trzaskoma, Q., …, Corya, S. (2008). Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485–492.
   PubMed Web of Science ®Google Scholar
• Serban, G., Siegel, S. (1984). Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry, 141, 1455–1458.
   PubMed Web of Science ®Google Scholar
• Shorter, E. (2009). Before Prozac. New York: Oxford University Press.
   Google Scholar
• Siever, L.J., Davis, K.L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647–1658.
   PubMed Web of Science ®Google Scholar
• Simpson, E.B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., Pearlstein, T. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379–385.
   PubMed Web of Science ®Google Scholar
• Soler, J., Pascual, J.C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., Pérez, V. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221–1224.
   PubMed Web of Science ®Google Scholar
• Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M., Ulrich, R.F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377–385.
   PubMed Web of Science ®Google Scholar
• Soloff, P., George, A., Nathan, R.S., Schulz, P.M., Ulrich, R.F., Perel, J.M. (1986a). Progress in pharmacotherapy of borderline disorders: A double-blind study of amitryptyline, haloperidol, and placebo. Archives of General Psychiatry, 43, 691–697.
   PubMed Web of Science ®Google Scholar
• Soloff, P.H., George, A., Nathan, S., Schulz, P.M., Ulrich, R.F., Perel, J.M. (1986b). Amitriptyline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin, 22, 177–182.
   PubMedGoogle Scholar
• Soloff, P.H., George, A., Nathan, S., Schulz, P.M., Cornelius, J.R., Herring, J., Perel, J.M. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238–246.
   PubMedGoogle Scholar
• Stoffers, J., Vo¨llm, B.A., Ru¨cker, G., Timmer, A., Huband, N., Lieb, K. (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD005653. DOI: 10.1002/ 14651858.CD005653.pub2.
   Web of Science ®Google Scholar
• Tritt, K., Nickel, C., Lahmann, C., Leiberich, P.K., Rother, W.K., Loew, T.H., Nickel, M.K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287–291.
   PubMed Web of Science ®Google Scholar
• Tyrer, P., Bateman, A.W. (2004). Drug treatment for personality disorders. Advances in Psychiatric Treatment, 10, 389–398.
   Google Scholar
• Verkes, R.J., Van der Mast, R.C., Hengeveld, M.W., Tuyl, J.P., Zwinderman, A.H., Van Kempen, G.M. (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry, 155, 543–547.
   PubMed Web of Science ®Google Scholar
• Wilcox, J.A. (1995). Divalproex sodium as a treatment for borderline personality disorder. Annals of Clinical Psychiatry, 7, 33–37.
   PubMedGoogle Scholar
• Zanarini, M.C., Frankenburg, F.R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849–854.
   PubMed Web of Science ®Google Scholar
• Zanarini, M.C., Frankenburg, F.R., Khera, G.S., Bleichmar, J. (2001). Treatment histories of borderline inpatients. Comprehensive Psychiatry, 42, 144–150.
   PubMed Web of Science ®Google Scholar
• Zanarini, M.C., Frankenburg, F.R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167–169.
   PubMed Web of Science ®Google Scholar
• Zanarini, M.C., Frankenburg, F.R., Dubo, E.D., Sickel, A.E., Trikha, A., Levin, A. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155, 1733–1739.
   PubMed Web of Science ®Google Scholar
• Zanarini, M.C., Frankenburg, F.R., Parachini, E.A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903–907.
   PubMed Web of Science ®Google Scholar
• Ziegenhorn, A.A., Roepke, S., Schommer, N.C., Merkl, A., Danker-Hopfe, H., Perschel, F.H., …, Lammers, C.H. (2009). Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 29, 170–173.
   PubMed Web of Science ®Google Scholar